Hepatitis C virus (HCV) has a propensity to cause chronic infection, with a low proportion of patients exhibiting a sustained response to interferon-␣ (IFN␣) therapy. An earlier report suggested that HCV inhibits IFN␣-induced signal transduction through the Jak/Stat pathway by preventing the formation of the transacting factor ISGF3 complex, although the effect on downstream pathway and the specific viral protein responsible for inhibition of IFN␣-mediated signal transduction were not elucidated. HCV core protein displays a number of intriguing functional properties and has been implicated in virus-mediated pathogenesis. In this study, we have analyzed the effect of core protein upon IFN␣-or IFN␥-induced regulation of the Jak/Stat signaling pathway. HCV core protein expression exhibited a reduced Stat1 expression in IFN-treated mammalian cells. A gel retardation assay suggested a reduced level of formation of the transacting factors, GAF and ISGF3, in IFN-treated cells. Further studies from protein expression and RNase protection assay revealed that the reduced level of GAF or ISGF3 formation could be attributed to modulation of Stat1 protein expression, an important player for innate immunity in host defense mechanism. However, these modulatory effects did not interfere with the activation of the downstream effector genes, IRF-1 and 561, in IFN-treated cells. Stable transfectants of cells after introduction of a plasmid DNA encoding both the structural and the nonstructural proteins of HCV also exhibited a similar effect. Taken together, these results suggest that although expression of the core protein alone or with other HCV proteins modulate transacting factors of Jak/Stat signaling pathway, expression of the downstream effector genes IRF-1 and 561 remains unaffected upon IFN treatment and may contribute to host defense mechanism.
INTRODUCTION
Hepatitis C virus (HCV) often causes a prolonged and persistent infection in humans. The most important feature of persistent HCV infection is the development of chronic hepatitis in half of the infected individuals, and the potential for disease progression to hepatocellular carcinoma (Saito et al., 1990; DiBisceglie et al., 1998; Hayashi et al., 1999; Jeffers, 2000) . This has been attributed in part to the effect of viral gene product(s) on the expression of host cellular genes. Unfortunately, a number of important issues related to HCV persistence and disease progression are unknown at this time. Furthermore, neither a vaccine nor any other means of an effective chemotherapy is available to eradicate HCV infection. HCV genotypes 1a and 1b are predominant in patients with chronic hepatitis C in the United States (Zein et al., 1996) , and interferon-␣ (IFN␣) alone or in combination with ribavirin is the current available therapy (Martin et al., 1998) . However, a significant number of cases do not respond well to therapeutic treatment, and the reason is not clear (Moradpur and Blum, 1999; Guidotti and Chishari, 2000) .
Signal transducers and activators of transcription (STATs) have drawn considerable attention due to their unique mode of action, and diversity of biological effects, which include the ability to control an immune response and an antiviral effect and to participate in cell transformation (Ihle, 1996; O'Shea, 1997) . IFN␣ and IFN␥ bind to their respective cell surface receptors and activate distinct but related signal transduction pathways, culminating in the activation of an overlapping set of interferonsensitive genes (ISGs). Upon binding of IFN␣/␤ to receptors, their associated protein kinases (Jak1 and Tyk2) phosphorylate Y701 of Stat1 and Y690 of Stat2. Stat1 and Stat2 then heterodimerize, translocate to the nucleus, and associate with p48 to form ISG factor 3 (ISGF3). ISGF3 activates the transcription of genes containing IFN-stimulated response elements (ISREs) within their promoters. The full activity of Stat1 also depends upon the phosphorylation of S727 via the mitogen-activated protein kinase pathway. On the other hand, IFN␥ upon binding to specific receptors will similarly phosphorylate Y701 of Stat1 through their associated protein tyrosine kinases (Jak1 and Jak2). Phosphorylated Stat1 homodimerizes to form ␥-activated factor (GAF), which activates the transcription of genes containing ␥-activated sequence (GAS) elements within their promoters. Phosphorylation of Stat1 on S727 is also required for the full activity of GAF (Darnell et al., 1994; Stark et al., 1998) .
MHC class II expression is controlled predominantly at the level of transcription (Boss, 1997) . IFN␣/␤ and IFN␥ has been shown to enhance the expression of MHC class I and MHC class II molecules (Taniguchi et al., 2001) . The expression of MHC class II molecules is also uniquely regulated by IRF-1, via an indirect mechanism. The expression of CIITA, a critical transcription factor for MHC class II gene induction by IFN␥, requires Stat1 and IRF-1 (Muhlethaler-Mottet et al., 1998; Piskurich et al., 1999) . IFN␥ can induce transcription of genes through many different cis elements (Leonard and Sen, 1996; Muhlethaler-Mottet et al., 1998) . GAS has been found in the regulatory regions of the high-affinity IgG receptor gene, the IRF-1 gene, and the Ly-6A/E gene. The GAS element is both necessary and sufficient to confer transcriptional activation of IRF-1 gene by IFN␥.
The genomic region encoding the HCV core protein is located between amino acids 1 and 191 and is likely to be the first gene product synthesized in virus-infected cells due to its localization at the 5Ј end of the HCV polyprotein transcript. In addition to its ability to interact with the viral genomic region to form nucleocapsids (Shimoike et al., 1999) , the presence of a putative DNAbinding motif, nuclear localization signals, phosphorylation sites, and a nucleocytoplasmic localization of the core protein suggest its possible function as a gene regulatory protein (Shih et al., 1993) . A role for HCV core protein in the transcriptional regulation of cellular promoters has been observed (Kim et al., 1994; Ray et al., 1995 Ray et al., , 1997 Ray et al., , 1998b Chang et al., 1998; Shrivastava et al., 1998; Lu et al., 1999; Ray et al., 2000; Otsuka et al., 2000; Bergqvist and Rice, 2001 ). In the course of these studies on transcriptional regulation, we have analyzed a number of core protein-associated functional properties, including the regulation of apoptotic cell death and the promotion of cell growth (Ray et al., 1996a (Ray et al., ,b, 1998a (Ray et al., , 1997 . While all of these functions may be important in ensuring the survival of HCV in the human host, the precise mechanism of core protein-mediated functions has yet to be delineated.
An earlier report using an inducible system expressing the entire HCV open reading frame in human osteosarcoma cells suggested that HCV inhibits IFN␣-induced signal transduction through the Jak/Stat pathway by preventing the formation of the transacting factor ISGF3 complex (Heim et al., 1999) . However, the specific viral protein responsible for an inhibition of IFN␣-mediated signal transduction and the effect on downstream pathway was not examined. In this study, we have investigated whether the expression of HCV core protein alone and together with other HCV proteins may modulate the cytokine-inducible gene expression of the Jak/Stat signal transduction pathway in IFN␣-or IFN␥-treated cells. Our results suggest that expression of HCV protein(s) modulates the formation of the GAF and ISGF3 complexes but does not interfere with the IFN-stimulated activation of the downstream IRF-1 or 561 gene.
RESULTS

Effect of HCV protein on Stat1 expression in IFNtreated cells
Interferon treatment of cells causes immediate activation of the transacting factor GAF and ISGF3. Once activated they translocate from cytoplasm to nucleus, bind to the ISRE or GAS element of IFN inducible genes, and activate their transcription. Since Stat1 is a component of both the activation factors GAF and ISGF3 complex, the distribution of Stat1 was investigated by an indirect immunofluorescence using mock transfected control, or stable transfectants of HeLa cells expressing core protein alone or together with other HCV proteins in untreated and IFN-treated cells. Additionally, stable transfectants of HeLa cells expressing CD4 antigen (HeLaT4) was included in this experiment to verify the effect of an unrelated ectotopic protein expression upon translocation of Stat1 following IFN treatment. Untreated cells exhibited a weak intracellular localization of the Stat1 protein (Figs. 1a, 1d, 1g , and 1j). However, a bright nuclear fluorescence of Stat1 was observed upon treatment of control HeLa or HeLa T4 cells with IFN␣ or IFN␥ (Figs. 1b, 1c, 1k, and 1l) . In contrast, a diffuse and predominantly perinuclear localization of Stat1 was observed in IFN-treated HeLa cells expressing core protein alone or together with other HCV proteins (Figs. 1e, 1f, 1h, and 1i) . IFN␣ or IFN␥ treatment of HCV protein expressing HT1080 or HepG2 cells exhibited a relatively weak nuclear translocation of Stat1 when compared to the mock transfected control (data not shown). Thus, HCV core protein is probably modulating the Jak/Stat pathway at a stage prior to GAF or ISGF3 activation.
HCV core protein expression reduces the level of IFN-induced GAF and ISGF3 transacting factors
To investigate the possible role of HCV core protein in GAF or ISGF3 activation, a gel retardation assay was performed. IFN-treated or untreated HeLa, HepG2, and HT1080 cells stably expressing core alone or together with other HCV proteins were used for this purpose. Mock transfected cells were separately used as control. Formation of a DNA-protein complex with the mobility and specificity of GAF was observed in both HeLa and core expressing HeLa cells following IFN␥ treatment. The image of the separation profile is shown in Fig. 2A . The specificity of GAF complex was verified using an anti-Stat1 antibody which disrupted the intensity of the GAF-DNA complex. While use of an anti-Stat2 antibody or unrelated antibody (data not shown in figure) as control did not inhibit GAF-DNA complex formation. In some cases, addition of antibody disrupts the formation of the complex rather than further changing its mobility (Sambrook and Russell, 2001 ). This may be due to high affinity of the antibody to Stat1, resulting in competition of the DNA binding sites for complex formation. Our observation of a decreased intensity of the GAF complex using an antibody to Stat1 is similar to those reported earlier by other investigators (Li et al., 1998 (Li et al., , 1999 . The uncharacterized band below GAF appeared in extracts of both untreated and IFN-treated cells, as observed earlier (Levy et al., 1990; Li et al., 1998) . This complex was specifically inhibited by antibody to Stat1 or Stat2; however, anti-Stat2 antibody did not inhibit GAF formation.
These complexes may represent inactivated heteromeric form of the Stats and awaits further characterization.
Densitometric scanning of the autoradiogram suggested that the GAF-DNA complex is ϳ4.8-fold higher in mock transfected control cells as compared to the core protein transfected HeLa cells ( Figs ISGF3-DNA complex formation was also analyzed using ISRE as a probe in IFN␣-treated control and coreexpressing HeLa cells (Fig. 3A) . The mobility and specificity of the ISGF3-DNA complex was verified using Stat-specific antibodies which competed with the protein-DNA complex formation. The ISGF3-DNA complex was ϳthreefold higher in mock transfected HeLa control as compared to core or HCV 1-2962 -transfected HeLa cells (Fig. 3B) . A similar result of ϳthreefold higher ISGF3-DNA complex formation was observed in the control over core-transfected HT1080 cells (Figs. 3C and 3D) and in HepG2 cells (data not shown). The gel shift assays for GAF and ISGF3 DNA complex formation were reproducible from at least three different experiments. Together, our results indicated that the HCV core protein modulates both GAF and ISGF3 protein complex formation in IFN-treated cells. 
Effect of IFN on expression of the signaling proteins
Our results indicated that HCV core-protein expression lowers the level of GAF and ISGF3 in IFN-treated cells. Thus, we investigated the protein expression level of Stat1 and p48 in control and core-expressing HeLa cell lysates by Western blot analysis using specific antibodies. Results suggested an approximately threefold decrease in Stat1 protein expression in core-expressing HeLa cells than mock transfected control cells (Fig. 4A) . However, the level of p48 remained similar in both the experimental and the control cells (Fig. 4C) .
The phosphorylated Stat1 level was also investigated in IFN␣-treated control and experimental HeLa cells by immunoprecipitation. Cell lysates were immunoprecipitated by a Stat1 monoclonal antibody and subjected to Western blot analysis using an antibody directed to the phosphotyrosine of Stat1 (Fig. 4B) . The phosphorylated form of the Stat1 protein was barely detectable in coreexpressing HeLa cells and could be due to lower Stat1 expression in HeLa cells. In contrast, phosphorylated Stat1-␣ polypeptide was clearly visible in mock transfected HeLa cells. A relatively lower level of Stat1 protein expression was also observed in HCV core-transfected HT1080 (Fig. 4E ) and HepG2 cell lysates (Fig. 4H) . On the other hand, expression level of the DNA binding protein p48 was similar in both cell lines (Figs. 4F and 4I) . Cellular actin was used as an internal control for comparison (Figs. 4D, 4G, and 4J ). Further examination of Stat1 mRNA expression by RNase protection assay suggested that the level of Stat1 increases greater than twofold following IFN␣ treatment in mock transfected HeLa cells than HCV core-expressing cells (Fig. 5) . Similar observations were made from cells treated with IFN␥ (data not shown). All of the experiments presented in Figs. 4 and 5 are representative of at least three independent experiments exhibiting similar results. These results suggested that HCV core protein modulates Stat1 expression at the transcriptional level. Thus, the core protein appears to modulate the Jak/Stat pathways by lowering the abundance of Stat1 protein.
HCV protein(s) does not inhibit induction of IFN stimulated genes
ISRE-mediated signaling was examined from the level of gene induction of two alternative IFN signaling pathways. IRF-1 mRNA is induced by IFN␥ with GAS as a cis element and GAF as the transcription factors. On the other hand, 561 mRNA is induced by IFN␣ using ISRE as a cis element and ISGF3 as cognate transcription factor. Cellular levels of the IFN␥-inducible IRF-1 mRNA and IFN␣-inducible 561 mRNA were analyzed by RNase protection assay. Activation of the IRF-1 mRNA upon IFN treatment (500 U/ml) was observed at a similar level for at least up to 12 h in both mock transfected and core or HCV protein expressing HeLa cells (Figs. 6A and 6B) , and a similar result was observed using a lower dose (100 U/ml) of IFN␥ (data not shown). Activation of IRF-1 mRNA was also observed following IFN␥ treatment of HepG2 cells (Figs. 6C and 6D) . Investigation for 561 gene induction suggested an increase in mRNA level within Immunoprecipitates were separated by SDS-8% PAGE and transferred onto nitrocellulose for probing with a monoclonal antibody to phosphotyrosine conjugated with horseradish peroxidase. Phosphorylated tyrosine moieties of Stat1-␣ were detected by chemiluminescence (b). Expression levels of Stat1-␣/␤ and p48 were analyzed by Western blot using a monoclonal antibody to Stat1-␣ (a, e, and h) and a polyclonal antibody to p48 (c, f, and i). An antibody to cellular actin was used as an internal control (d, g, and j). Arrows on the right indicate the respective polypeptides, and their molecular sizes correlated with the migration of standard molecular weight markers (Gibco BRL). 6 h of IFN␣ treatment, which then decreased slightly between 6 and 12 h in HepG2 cells (Fig. 6E) . The reason for this decline of 561 mRNA is unclear at present. Time-dependent activation of 561 was also observed in HeLa cells (data not shown). These results suggested that even a reduced level of GAF or ISGF3 complex is sufficient to activate the interferon-stimulated downstream effector genes of Jak/Stat signaling pathways, and this effect appeared to be dependent upon IFN stimulation.
DISCUSSION
Results from this study indicate that expression of core protein alone or together with other HCV proteins modulates the transacting factors GAF or ISGF3 of the IFNinduced Jak/Stat signaling pathway. This may be related to a decreased abundance of the Stat1 protein and/or a weak translocation of Stat1 to the cell nucleus. However, these modulatory effects do not interfere with IFN-induced downstream activation of the IRF-1 and 561 gene expression. We have used ectopic expression of HCV protein in this study as that will be more relevant to the nature of chronic HCV infection, when IFN␣ treatment is normally offered. Our results from expression of HCV proteins agree in part with the reduced GAF or ISGF3 formation observed following inducible expression of the entire HCV open reading frame in osteosarcoma cells (Heim et al.,1999) , although a difference in Stat1 expression level was observed in our study. This difference in results could be attributed to inducible vs stable expression system and the nature of the cell lines used. Our study also suggests a difference in expression level based on the cell types used. However, our results indicate that even a reduced level of GAF or ISGF3 complex in IFN-treated cells is sufficient to activate IS genes, IRF-1 and 561. Thus, we find evidence to suggest a role for the HCV core protein in the inhibition or impairment of the Stat1 expression, which can be augmented by IFN treatment for induction of the downstream effector gene of Jak/Stat pathway in HeLa, HT1080, or HepG2 cells.
IFN␣ regulates the function of cytokines, their receptors, and other molecules of immune importance (Goodbourn et al., 2000) . A large number of genes are induced by IFN␣, but only a few of these gene products have been associated with an intrinsic antiviral activity. Those identified include the p68 protein kinase (PKR) and 2Ј-5Ј-oligoadenylate synthetase (2Ј-5Ј-OAS), which are both dependent upon double-stranded RNA for activity, certain MxA family proteins, and the most recently identified promyelocyte leukemia protein (Goodbourn et al., 2000) . While IFN-treated cells are resistant to many different viruses, individual overexpression of these intrinsically antiviral proteins confers host resistance only against some viruses. HCV E2 and NS5A proteins have been implicated in IFN resistance through inhibition of PKR (Gale et al., 1997 (Gale et al., , 1998 Taylor et al., 1999) . Inhibitory properties of HCV E2 glycoprotein may occur by mimicking the autophosphorylation site via a pseudosubstrate mechanism (Taylor et al., 2001) . PKR inhibition by E2 or NS5A protein may contribute but do not solely explain the resistance to sustained IFN treatment Francois et al., 2000; Gerotto et al., 2000) . In chronic HCV patients, the expression of 2Ј-5Ј-OAS and MxA are not significantly different at the hepatic mRNA level when compared with chronic HBV or other liver diseases of different etiology (Yu et al., 2000) . HCV core protein also activates 2Ј-5Ј-OAS gene in hepatocyte cell lines, which is further enhanced upon treatment with interferon (Naganuma et al., 2000) . Unfortunately, the lack of a suitable virus-cell culture system for study of HCV growth does not allow the study the contribution of IFN induced proteins for antiviral response at this time.
The function of Stat1 is to regulate a set of genes that collectively provide innate immunity (Ihle, 1996) . The homozygous mutant cells and animals devoid of functional Stat1 protein revealed that Stat1 is indispensable for the IFN pathway, but may not be necessary for other signaling systems for normal development (Durbin et al., 1996) . However, mutant animals demonstrated the essential nature of Stat1-dependent system for survival in the face of otherwise innocuous viral pathogens. This may result from the combined loss of both type I and type II IFN responses, which has been shown to impair some antiviral responses (van den Broek et al., 1995) . Stat1-dependent innate immunity, presumably produced in response to IFN, appears to be a crucial host defense mechanism combating mouse hepatitis virus (MHV) disease. A majority of humans fail to develop protection against HCV infection and Stat1 modulation by core protein may contribute to this defect.
Although Stats are translocated to the nucleus after activation, neither the mechanism underlying this translocation nor the reason for their retention in the cytoplasm prior to stimulation is well understood (O'Shea, 1997). Two mechanisms, ubiquitination and dephosphorylation, have been proposed for attenuating Stat activation. However, the relative importance of these two mechanisms and the identity of the Stat phosphatase are not known. A recent report suggests a complex of unphosphorylated Stat1 and IRF-1 transcribes the LMP2 gene, which would involve them in the processing of viral and tumor antigens for presentation to CD8 ϩ T cells in the context of MHC class I molecules (ChatterjeeKishore et al., 2000) . IFN␥ is a potent inducer of MHC class II expression and is activated through Jak/Stat pathway. Regulation of MHC class II gene expression by IFN␥ and other modulators occur primarily at the mRNA transcription, although posttranscriptional modulation has been described. The results from our study are in agreement with the observations that HCV core protein does not disrupt the expression of MHC class II molecules on cell surface (Hiasa et al., 1998; Large et al., 1999) . Our data suggest that the core protein when constitutively expressed in cells decreases Stat1 expression, the level of which differs depending on the cell type used. However, this effect can be overcome by IFN treatment to induce the downstream effector gene expression of the Jak/Stat signaling pathways. Stat1 also plays an important role in growth arrest, in promoting apoptosis, and is implicated as a tumor suppressor (Bromberg and Darnell, 2000) . Cross talk between Stat and other cellular signaling pathways can be achieved by the action of certain Stat-associated proteins. For example, an interaction between ERK and Stat may connect the MAPK and Stat signaling pathways (Shuai, 2000) . IFN␥, which activates large amounts of Stat1, decreases the AP1-and ETS-mediated transcriptional increase, possibly by competing for CBP, p300, or both (Darnell, 1997) . Stats may have direct effects on inhibiting proliferation by induction of cyclin-dependent kinase inhibitors, such as p21/Waf1 (Chin et al., 1996) . This may explain the antiproliferative effects of interferons. Interestingly, a reduced level of p21/Waf1 protein expression in HCV-related hepatocellular carcinoma has been reported (Shi et al., 2000) . Our present results coupled with the previous observations made on the effect of HCV core protein mediated modulation of AP-1, MAPKK, and p21/Waf1 (Hayashi et al., 2000; Ray et al., 1998b; Shrivastava et al., 1998; Tsuchihara et al., 1999) suggest that core protein may target a number of cellular genes that could have a concerted action on normal cell growth checkpoint control. HCV has a uniquely adapted mechanism to inhibit host antiviral effector pathways, ensuring survival in the human host. Studies on expression of some of IFN-regulated genes in the liver of chronic HCV patients (Meier et al., 2000; Patzwahl et al., 2001; Yu et al., 2000) does not suggest a clear picture for their contribution in anti-HCV response. A complex gene network is involved in the regulation of the IFN system. In fact, the 5Ј regulatory region of the IRF-1 gene has been shown to contain highly GC-rich sequences and consensus binding sequences for several known transcription factors, including NF-B . However, our observations do not support such an alternative effect, especially when results from IFN␣ and IFN␥ are considered, since both of these pathways are partially overlapping through Stat1. Even though our results suggest that IFN-stimulated genes of the Jak/Stat pathway are not impaired or blocked by HCV proteins, the relative weakness of IFN␣ therapy may arise from virus-mediated interruption of other gene products with antiviral activity or from the nature of poor antiviral activity associated with human hepatocytes.
MATERIALS AND METHODS
Cell lines, plasmid construct, and protein expression
Human cervical carcinoma (HeLa) and human hepatoma (HepG2) cells were obtained from the American Type Culture Collection (Rockville, MD). The human fibrosarcoma epithelial-like HT1080 cells were kindly provided by G. R. Stark (Cleveland Clinic Foundation, OH) . Cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum. A full-length HCV clone (kindly provided by C. M. Rice, Washington University, St. Louis, MO) was digested with suitable restriction enzymes and the genomic region representing the structural and nonstructural proteins (amino acids 1-2962) was subcloned into a pCIneo mammalian expression vector, introducing a stop codon at the translational end. Cloning of the HCV genomic region representing the core protein (amino acids 1-191) has been described earlier (Ray et al., 1995) . Subconfluent cell monolayers were transfected with a mammalian expression vector containing HCV (pCIneo/ HCV 1-2962 ) or HCV core (pcDNA3/Core 1-191 ) gene using lipofectamine (Gibco BRL, MD). An empty vector DNA was transfected into cells for use as a control. Neomycin-resistant stable transfectants were pooled to avoid clonal selection and tested for integration of HCV gene and protein expression. Stable cell transfectants exhibited NS5A and/or core protein expression (depending on the plasmid transfected) separately by Western blot analysis and indirect immunofluorescence (Ray et al., 1996b) using monoclonal antibodies (mAbs) to NS5A protein (Biogenesis, Inc., MA) or core protein (C7-50, kindly provided by Jack R. Wands, Harvard Medical School, MA). Additionally, cells transfected with the pCIneo/HCV 1-2962 gene exhibited distinct immunofluorescence with monoclonal antibody to E1 or E2. Transfected cells did not exhibit unusual growth characteristics and were analyzed for the role of viral protein(s) in IFN signaling pathways.
Immunofluorescence
Stable cell transfectants were examined for subcellular localization of Stat 1 expression by a specific mAb (Santa Cruz Biotechnology, CA). Briefly, cells grown overnight on coverslips were left untreated or treated with IFN␥ (500 U/ml) or IFN␣ (1000 U/ml) for 30 min. Cells were washed and then fixed with methanol/acetone (1:1) for 2 min. After washing, cells were incubated with the mAb at room temperature for 1 h, washed, and stained with a goat anti-mouse IgG conjugated to fluorescein isothiocyanate. A human CD4 gene stably transfected into HeLa cells was also included as an unrelated control in similar immunofluorescence study.
Immunoprecipitation and Western blot analysis
Cells were treated with 1000 U/ml IFN␣ or 500 U/ml of IFN␥ for 90 min, washed, and lysed in 1ϫ lysis buffer (0.5% NP-40, 50 mM Tris-HCl, pH 8.0, 10% glycerol, 0.1mM EDTA, 300 mM NaCl, 1mM DTT, and a cocktail of protease inhibitors) for 1 h on ice. Cell lysates were incubated with a monoclonal antibody to Stat1-␣ at 4°C and the immunoprecipitate was immobilized onto protein A-Sepharose CL-4B (Pharmacia, NJ). The sample was subjected to electrophoresis on a SDS-polyacrylamide gel. Proteins were transferred onto a nitrocellulose membrane and blocked with 5% low-fat milk. HRP-conjugated anti-human phosphotyrosine monoclonal antibody (Santa Cruz Biotechnology) was used for detection of the phosphorylated form of the Stat1 polypeptide. Stat1 and p48 protein expression was also determined directly from cell lysates by Western blot analysis using specific monoclonal and polyclonal antibodies, respectively (Santa Cruz Biotechnology). An antibody to cellular actin (Oncogene Research, CA) was used as a control in Western blot for analyzing protein load in each lane. A HRP-conjugated second antibody to mouse Ig was used to visualize the protein bands by enhanced chemiluminescence (ECL; Amersham, IL).
Gel retardation assay
The gel retardation assay for GAF and ISGF3 was performed as previously described (Leonard and Sen, 1996) . Briefly, cells were treated for 30 min with1000 U/ml of IFN␣ or 500 U/ml of IFN␥ and untreated cells were used as control. Cells were lysed with NP-40 in low-salt buffer (10mM HEPES, pH 7.9; 10 mM KCl, 0.1 mM EDTA, 1 mM DTT, 0.5mM PMSF, and a cocktail of protease inhibitors) on ice for 5 min. The nuclear pellet was collected by centrifugation and suspended in a high-salt buffer (20 mM HEPES, pH 7.9; 0.4 mM NaCl, 0.1 mM EDTA, 1 mM DTT, and 1 mM PMSF) for 30 min at 4°C. Nuclear extracts were obtained by centrifugation at 12,000 g, and aliquots were flash frozen immediately for storage at Ϫ70°C. The protein concentration of the nuclear extracts were determined using protein assay reagent (Bio-Rad, CA). The GAS element located between Ϫ129 and Ϫ106 of the IFN␥-inducible IRF1 gene, and ISRE element located between Ϫ125 and Ϫ93 of the IFN␣ 561 gene (Leonard and Sen, 1997) , were used as probes (kindly provided by G. C. Sen, Cleveland Clinic Foundation, OH) for our studies. The annealed doublestranded probes were end labeled with [␣- 32 P]dCTP using a DNA polymerase to fill in the ends. Gel retardation assay was initially standardized by varying the quantity of the nuclear extracts in obtaining a linear range of detection of the specific complexes. Finally, 10 g of nuclear proteins were incubated with 32 P-labeled oligonucleotide probe in the presence of poly[d(I-C)] in a binding buffer (50 mM HEPES, pH 7.5; 250 mM NaCl, 2.5 mM EDTA, 1mM MgCl 2 , 2.5 mM DTT, and 1 mM PMSF, 5 mM MgCl 2 , 20% glycerol, and a cocktail of protease inhibitors) for 30 min at room temperature. The specificity of the Stat1 protein in DNA-protein complex was identified by adding a murine monoclonal antibody to Stat1 (Santa Cruz) to the reaction mixture before formation of the complex. A rabbit polyclonal antibody to Stat2 (Santa Cruz), unrelated murine monoclonal antibodies, or fetal calf serum as negative controls, were used separately for determining the inhibitory effect on DNA-protein complex formation. The samples were electrophoresed until the free radiolabeled probe was removed from the nondenaturing 5% polyacrylamide separation gel and exposed to X-ray film for autoradiography. The autoradiogram was scanned densitometrically for a comparison of band intensity.
RNase protection assay
The induction of Stat1, IRF-1, and 561mRNAs were analyzed using specific probes as described earlier (Kalvakolanu et al., 1991; Leonard and Sen, 1997) . A 409-nucleotide fragment of the Stat1 gene (Pharmingen, CA), a 175-nucleotide fragment (nucleotide positions 192-367) of the IRF-1 gene, or 142-nucleotide fragment (nucleotide positions 1369-1511) of the 561 gene (kindly provided by G. C. Sen) was used as a probe. A 113-nucleotide-long L32 and 128-nucleotide-long ␥-actin probe was used for internal control. Briefly, total RNA was isolated from cells, with or without IFN treatment, using a RNA isolation kit (Gentra Systems, MN). An antisense RNA probe was labeled with [ 32 P]UTP and cold NTPs using SP6 or T7 RNA polymerase. The probe was hybridized in excess to target cellular RNA (2 g) overnight. Free probe and single-stranded RNA were digested with RNAseA and RNAseT1, followed by proteinase K treatment. The protected RNA was recovered by phenol/chloroform extraction, ethanol precipitation, and identified by resolving on a 5% urea-polyacrylamide gel by electrophoresis, followed by autoradiography. The protected RNA band in the autoradiogram was densito-metrically scanned to quantitate intensity after normalization against the L32 or ␥-actin as an internal control.
